Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0IUMMH
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
WO2018098269A2 conjugate 43A
|
|||||
| Synonyms |
WO2018098269A2_conjugate-43A
Click to Show/Hide
|
|||||
| Organization |
Mersana Therapeutics, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 3 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Gastric cancer [ICD11:2B72]
Investigative
Ovarian cancer [ICD11:2C73]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
6.6
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
WO2018098269A2_conjugate 43A linker
|
|||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.